-
LINKING QUALITY AND FINANCIAL PERFORMANCE: A FIVE-YEAR LONGITUDINAL ANALYSIS OF ROI IN MEDICARE PIONEER ACOS
Mar 18, 2026, 21:38 PM -
DIFFERENCES IN THE DIETARY HABITS AND RISK FACTORS FOR METABOLIC DISEASES BETWEEN WESTERN AND EASTERN EUROPE
Mar 18, 2026, 21:38 PM -
2026 REVIEW OF GENE THERAPY ACCESS LANDSCAPE
Mar 18, 2026, 21:38 PM -
IDENTIFYING PREDICTORS OF HIGH-COST CARE IN GENERALIZED PUSTULAR PSORIASIS: INSIGHTS FROM U.S. REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
THE SCALE OF PROLONGED UNCERTAINTY: ESTIMATING U.S. PATIENT POPULATIONS AFFECTED BY OVERDUE ACCELERATED APPROVAL CONFIRMATORY TRIALS
Mar 18, 2026, 21:38 PM -
VALIDATION OF THE METASLR ROB MODULE: A MULTI-AGENT GENERATIVE AI SYSTEM FOR AUTOMATING COCHRANE RISK OF BIAS 2.0 ASSESSMENTS
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT OF INTRODUCING TAPINAROF, A NEW ARYL HYDROCARBON RECEPTOR AGONIST, FOR THE TREATMENT OF ATOPIC DERMATITIS IN ADULT AND PEDIATRIC PATIENTS, FROM A U.S. MEDICAID PLAN PERSPECTIVE
Mar 18, 2026, 21:38 PM -
CROSS-VALIDATION OF AN EARLY COST-EFFECTIVENESS MODEL FOR SPECTRIS™ THERAPY USING THE ALZHEIMER’S DISEASE OPEN-SOURCE IPECAD MODEL FRAMEWORK
Mar 18, 2026, 21:38 PM -
FROM SINGLE-ARM EVIDENCE TO HTA-READY SURVIVAL COMPARISONS: EXTENDING MULTILEVEL NETWORK META-REGRESSION TO DISCONNECTED NETWORKS FOR TIME-TO-EVENT OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Mar 18, 2026, 21:38 PM -
REPRESENTATIVENESS OF LINKED CLAIMS-EHR DATA: CLAIMS-ONLY VS CLAIMS+EHR POPULATIONS
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING-BASED PREDICTION FOR NEPHROTOXICITY IN ONCOLOGY PATIENTS WITH CHEMOTHERAPY
Mar 18, 2026, 21:38 PM -
CHARACTER STRENGTHS AND BURNOUT DIMENSIONS AMONG EMERGENCY CARE PROFESSIONALS IN HUNGARY: A CROSS-SECTIONAL STUDY
Mar 18, 2026, 21:38 PM -
FIRST-LINE SYSTEMIC TREATMENT PATTERNS IN METASTATIC UROTHELIAL CARCINOMA IN US COMMUNITY ONCOLOGY PRACTICES
Mar 18, 2026, 21:38 PM -
HEALTH ECONOMICS PUBLISHED EVIDENCE FOR FDA-APPROVED DRUGS (2022-2023): AVAILABILITY, TIMING & DISSEMINATION PATHWAY
Mar 18, 2026, 21:38 PM -
MODELING THE IMPACT OF SOTATERCEPT ON MORBIDITY AND MORTALITY IN PULMONARY ARTERIAL HYPERTENSION: A MEXICAN POPULATION HEALTH PERSPECTIVE
Mar 18, 2026, 21:38 PM -
GENERAL-PURPOSE VERSUS DOMAIN-SPECIFIC AI FOR SYSTEMATIC CONFOUNDER IDENTIFICATION IN MULTIPLE SCLEROSIS: A COMPARATIVE METHODOLOGICAL STUDY USING IQWIG ASSESSMENTS AS GROUND TRUTH
Mar 18, 2026, 21:38 PM -
EMPLOYEE PERCEPTIONS AND EXPERIENCES WITH TIRZEPATIDE TREATMENT FOR OBESITY OR OVERWEIGHT IN THE US
Mar 18, 2026, 21:38 PM -
REGULATORY CHALLENGES AND INSIGHTS FROM FDA IN 2025; POTENTIAL IMPLICATIONS OF THE PLAUSIBLE MECHANISM PATHWAY AND SUBSEQUENT HEALTH TECHNOLOGY ASSESSMENTS
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT ANALYSIS OF PATIENTS WITH NAMD OR DME WHO MAY REQUIRE MONTHLY DOSING WITH AFLIBERCEPT 8 MG
Mar 18, 2026, 21:38 PM -
ONE GLOBAL EVIDENCE PLAN FOR MANY DECISION-MAKERS: ALIGNING EVIDENCE FOR EU JCA, AMCP DOSSIER, AND ICER REVIEWS
Mar 18, 2026, 21:38 PM
